Milestone Scientific, Inc. MLSS
0.41
0.00
0.00%
as of 25 Sep
- Market cap
- $37.2M
- P/E
- 0.0×
Follow MLSS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.16 | 2.77 | 2.47 | 4.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(50.93) | 284.13 | (98.00) | 452.88 | |
P/B ratio |
8.59 | 10.79 | 7.88 | 14.53 | |
Price to Tangible BV |
8.70 | 11.09 | 8.11 | 15.10 | |
EV/Sales |
2.99 | 2.73 | 2.44 | 4.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(43.90) | (13.33) | (7.50) | (8.69) | |
EV/FCF |
(32.98) | (11.94) | (6.99) | (8.27) | |
Quick Ratio |
0.71 | 0.36 | 0.44 | 0.41 | |
Current Ratio |
1.85 | 1.51 | 1.81 | 1.61 | |
Net Debt/EBITDA |
1.57 | 0.48 | 0.28 | 0.47 | |
Debt/Assets |
5.75% | 10.30% | 10.60% | 9.83% | |
Debt/Equity |
0.14 | 0.36 | 0.29 | 0.33 | |
Asset Turnover |
1.15 | 1.04 | 1.02 | 0.91 | |
Operating CF/Net income |
0.55 | (0.10) | 0.21 | (0.07) | |
Capex/Depreciation |
(0.09) | (0.03) | (0.06) | (0.16) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.23% | 0.00% | 0.60% | 0.69% | |
Selling, General and Administrative Expense of Revenue |
103.68% | 109.75% | 123.90% | 116.05% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
14.05% | 14.44% | 25.97% | 15.38% | |
Graham Net Nets |
0.11 | 0.07 | 0.11 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.75%) | (18.62%) | (23.70%) | (18.67%) | |
Free Cash Flow Yield |
(2.87%) | (8.25%) | (14.12%) | (11.92%) | |
Revenue per Share |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.02 | 0.01 | 0.01 | 0.02 | |
Shareholders Equity per Share |
0.04 | 0.03 | 0.03 | 0.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.04 | 0.03 | 0.03 | 0.03 | |
Free Cash Flow |
(0.59) | 0.09 | (0.23) | 0.08 | |
Working Capital |
3.72 | 2.50 | 3.35 | 3.08 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
3.24 | 1.67 | 2.48 | 2.17 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(37.29%) | (38.85%) | (52.99%) | (48.90%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.87 | 0.55 | 0.59 | 0.64 | |
Average Payables |
2.41 | 2.97 | 2.15 | 2.46 | |
Average Inventory |
3.49 | 3.83 | 3.75 | 3.92 | |
Average Assets |
8.20 | 8.53 | 8.80 | 9.83 | |
Average Common Equity |
3.41 | 3.37 | 4.32 | 4.89 |
Columns are period end dates